7 Nisan 2025 Dergi makalesi Açık Erişim

Serilmez, Murat; Abuelrub, Anwar; Erol, İsmail; Durdagı, Serdar

JSON

{
  "conceptdoi": "10.48623/aperta.285983", 
  "conceptrecid": "285983", 
  "created": "2025-06-03T11:02:35.899612+00:00", 
  "doi": "10.48623/aperta.285984", 
  "files": [
    {
      "bucket": "c7bcdbcc-71c1-43b8-beab-2c45cd3abff8", 
      "checksum": "md5:7db218b4d47c514e16e47fbc29609411", 
      "key": "Supplementary Data revised 03062025.docx", 
      "links": {
        "self": "https://aperta.ulakbim.gov.tr/api/files/c7bcdbcc-71c1-43b8-beab-2c45cd3abff8/Supplementary%20Data%20revised%2003062025.docx"
      }, 
      "size": 1024997, 
      "type": "docx"
    }
  ], 
  "id": 285984, 
  "links": {
    "badge": "https://aperta.ulakbim.gov.tr/badge/doi/10.48623/aperta.285984.svg", 
    "bucket": "https://aperta.ulakbim.gov.tr/api/files/c7bcdbcc-71c1-43b8-beab-2c45cd3abff8", 
    "conceptbadge": "https://aperta.ulakbim.gov.tr/badge/doi/10.48623/aperta.285983.svg", 
    "conceptdoi": "https://doi.org/10.48623/aperta.285983", 
    "doi": "https://doi.org/10.48623/aperta.285984", 
    "html": "https://aperta.ulakbim.gov.tr/record/285984", 
    "latest": "https://aperta.ulakbim.gov.tr/api/records/285984", 
    "latest_html": "https://aperta.ulakbim.gov.tr/record/285984"
  }, 
  "metadata": {
    "access_right": "open", 
    "access_right_category": "success", 
    "creators": [
      {
        "affiliation": "\u0130stanbul \u00dcniversitesi", 
        "name": "Serilmez, Murat"
      }, 
      {
        "affiliation": "Bah\u00e7e\u015fehir \u00dcniversitesi", 
        "name": "Abuelrub, Anwar"
      }, 
      {
        "affiliation": "Bah\u00e7e\u015fehir \u00dcniversitesi", 
        "name": "Erol, \u0130smail"
      }, 
      {
        "affiliation": "Bah\u00e7e\u015fehir \u00dcniversitesi", 
        "name": "Durdag\u0131, Serdar"
      }
    ], 
    "description": "<p><strong>Background/Aim:</strong> The COVID-19 pandemic caused by SARS-CoV-2 necessitated rapid development of effective therapeutics, prompting this study to identify potential inhibitors targeting key viral proteins: RNA-dependent RNA polymerase (RdRp), main protease (Mpro), transmembrane serine protease 2 (TMPRSS2), and angiotensin-converting enzyme 2 (ACE2).</p>\n\n<p><strong>Methods:</strong> We employed covalent docking and molecular dynamics simulations to screen FDA-approved compounds against these targets using diverse covalent reaction mechanisms. Top-ranking compounds underwent further evaluation through molecular dynamics simulations to assess binding stability and conformational dynamics.</p>\n\n<p><strong>Results:</strong> Several promising drug repurposing candidates were identified: Bremelanotide, Lanreotide, histerlin, and Leuprolide as potential RdRp protein inhibitors; Azlocilin, Cefiderocol, and Sultamicillin for Mpro inhibition; Tenapanor, Isavuconazonium, and Ivosidenib targeting TMPRSS2; and Cefiderocol, Cefoperazone, and Ceftolozane as potential ACE2 inhibitors..</p>\n\n<p>&nbsp;<strong>Conclusion:</strong> This study provides valuable insights into repurposing existing drugs as potential COVID-19 therapeutics by targeting crucial viral proteins. However, further experimental validation and clinical studies are necessary to confirm the efficacy and safety of these compounds before consideration for clinical application.</p>", 
    "doi": "10.48623/aperta.285984", 
    "has_grant": true, 
    "keywords": [
      "Covid-19", 
      "covalent docking", 
      "Molecular dynamic simulation", 
      "molecular mechanics-generalised born surface area"
    ], 
    "license": {
      "id": "cc-by-nc-4.0"
    }, 
    "publication_date": "2025-04-07", 
    "related_identifiers": [
      {
        "identifier": "10.48623/aperta.285983", 
        "relation": "isVersionOf", 
        "scheme": "doi"
      }
    ], 
    "relations": {
      "version": [
        {
          "count": 1, 
          "index": 0, 
          "is_last": true, 
          "last_child": {
            "pid_type": "recid", 
            "pid_value": "285984"
          }, 
          "parent": {
            "pid_type": "recid", 
            "pid_value": "285983"
          }
        }
      ]
    }, 
    "resource_type": {
      "subtype": "article", 
      "title": "Dergi makalesi", 
      "type": "publication"
    }, 
    "science_branches": [
      "Sa\u011fl\u0131k Bilimleri > T\u0131p > Temel T\u0131p Bilimleri > Biyokimya"
    ], 
    "title": "FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: An in silico approach", 
    "tubitak_grants": [
      {
        "program": "DIGER", 
        "project_number": "118C494", 
        "workgroup": "SBAG"
      }
    ]
  }, 
  "owners": [
    2836
  ], 
  "revision": 1, 
  "stats": {
    "downloads": 0.0, 
    "unique_downloads": 0.0, 
    "unique_views": 0.0, 
    "version_downloads": 0.0, 
    "version_unique_downloads": 0.0, 
    "version_unique_views": 0.0, 
    "version_views": 0.0, 
    "version_volume": 0.0, 
    "views": 0.0, 
    "volume": 0.0
  }, 
  "updated": "2025-06-03T11:02:36.051584+00:00"
}